أرسل هذا في رسالة قصيرة: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

 __   __    _____     _____      ___      ______  
 \ \\/ //  |  ___||  / ____||   / _ \\   /_   _// 
  \   //   | ||__   / //---`'  | / \ ||  `-| |,-  
  / . \\   | ||__   \ \\___    | \_/ ||    | ||   
 /_//\_\\  |_____||  \_____||   \___//     |_||   
 `-`  --`  `-----`    `----`    `---`      `-`'